Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing ...

Dive into biosimilar regulations in the US! Test your knowledge with our quiz on FDA rules, naming tricks, post-market safety, and more. Ready for the challenge?

Sarfaraz K. Niazi, PhD, explains FDA's new guidance on promotional labeling as well as challenges and insights into how this ...

On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from ...

Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.

Number 5: Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that applying collective action theory can achieve widespread biosimilar ...

Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) ...

Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over ...

During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the ...

The FDA approved a high-concentration, citrate-free version of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), making it ...

April brought 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of ...